Objective: We attempted to investigate whether Phosphatidylinositol 3-kinase (PI3K) pathway-inhibitor would be effective in paclitaxel-resistance cervical cancer. Methods: Naive and palitaxel-resistant cervical tumor cells were used and a PI3K inhibitor was treated. Apoptosis analysis and invasion assay were performed. Results: PI3K inhibitor enhanced apoptosis and decreased invasion potency in paclitaxel-resistant cervical cancer. Conclusion: We suggest that PI3K inhibitor may enhance antitumor activity in cervical cancer.